Arcera Life Sciences a global life sciences firm based in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co Ltd, an innovation-led international pharmaceutical and healthcare company, have announced the signing of a Memorandum of Understanding (MoU). This agreement establishes a long-term strategic partnership focused on licensing, advancing technologies, driving neuroscience innovation, and creating value across the global life sciences landscape.
Aligned with the broader Comprehensive Strategic Partnership between China and the UAE, as well as Abu Dhabi’s Healthcare Life Sciences Vision 2030, the MoU aims to unlock new avenues for innovation and market access in both regions. By combining Fosun Pharma’s strong research, development, and manufacturing expertise with Arcera’s global commercial reach and market access capabilities, the partnership positions Abu Dhabi as a key gateway connecting Chinese biotech innovation with international markets. It also seeks to accelerate patient access to cutting-edge treatments across the Middle East and beyond.
Under the agreement, the two companies will explore collaboration in three primary areas:
Licensing opportunities at regional and global levels: Initial efforts will focus on identifying licensing prospects for Fosun Pharma’s portfolio, particularly in oncology, neuroscience, rare diseases, and cardiometabolic conditions. This includes therapies already in late-stage clinical development or commercialized in China. Development of advanced technologies: The partners will assess opportunities to establish joint ventures or new entities aimed at localizing advanced biotechnology in the UAE. This includes capabilities in small molecules, biologics, radiopharmaceuticals, small interfering RNA (siRNA) therapies, as well as cell and gene therapies. Neuroscience collaboration: A key focus will be on neurodegenerative disorders, including Alzheimer’s disease, addressing a major global health need where both innovation and access remain limited. Aligned with the broader Comprehensive Strategic Partnership between China and the UAE, as well as Abu Dhabi’s Healthcare Life Sciences Vision 2030, the MoU aims to unlock new avenues for innovation and market access in both regions. By combining Fosun Pharma’s strong research, development, and manufacturing expertise with Arcera’s global commercial reach and market access capabilities, the partnership positions Abu Dhabi as a key gateway connecting Chinese biotech innovation with international markets. It also seeks to accelerate patient access to cutting-edge treatments across the Middle East and beyond.
Under the agreement, the two companies will explore collaboration in three primary areas:
Isabel Afonso, CEO of Arcera, noted that the agreement represents a significant milestone in building a globally connected life sciences ecosystem anchored in the UAE. She emphasized that combining Fosun Pharma’s drug development expertise with Arcera’s commercial and manufacturing strengths creates a powerful model for accelerating innovation and improving patient access. She also highlighted that this partnership marks Arcera’s first major step in positioning Abu Dhabi as a link between Asian innovation and global markets.
Xingli Wang, Co-President of Fosun Pharma and CEO of its Innovative Medicines Division, described the partnership as an important step in expanding the company’s global footprint and strengthening international collaboration. He expressed confidence that Fosun Pharma’s decades of experience in R&D and manufacturing would support the partnership’s success and stated that both organizations aim to work closely together to bring innovative therapies to patients across the Middle East and worldwide.
Xingli Wang, Co-President of Fosun Pharma and CEO of its Innovative Medicines Division, described the partnership as an important step in expanding the company’s global footprint and strengthening international collaboration. He expressed confidence that Fosun Pharma’s decades of experience in R&D and manufacturing would support the partnership’s success and stated that both organizations aim to work closely together to bring innovative therapies to patients across the Middle East and worldwide.